Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease
Executive Summary
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
You may also be interested in...
Roche Partners With UCB On Anti-Tau Alzheimer’s Drug
UCB gets $120m up front from Roche for option rights to UCB0107 and retains full rights to the drug in progressive supranuclear palsy.
AC Immune CEO Outlines ‘Roadmap’ For Fighting Alzheimer’s
AC Immune’s CEO tells Scrip that treating earlier, targeting Tau, and focusing on more homogeneous populations will be needed to successfully fight Alzheimer’s Disease.
Open-Label Extensions The Key To Gantenerumab Success, Stresses Roche
Roche’s neuroscience strategy of following the science, taking on lessons from open label extensions from Phase III studies, is vital to the success of gantenerumab, the company said in an interview with Scrip.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports